THERAPEUTIC ALGORITHM FOR EARLY HER2+ BREAST CANCER

Abstract

HER2 positive breast cancer has its unique biological and clinical characteristics. The optimal approach for patients with HER2+ early breast cancer is a subject of discussion and decision by a multidisciplinary tumor board. The use of dual HER2 blockade in neoadjuvant setting for tumors larger than 2 cm or by lymph node involvement allows after surgical intervention evaluation of residual invasive disease and more precise determination of subsequent therapeutic approach.